Safety and dosimetry of [177Lu]Lu-DOTA-TATE in adolescent patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, or pheochromocytomas and paragangliomas: Primary analysis of the Phase II NETTER-P study
Sign Up to like & getrecommendations! Published in 2025 at "European Journal of Nuclear Medicine and Molecular Imaging"
DOI: 10.1007/s00259-025-07246-7
Abstract: NETTER-P, an open-label Phase II study, evaluated the safety and dosimetry of [177Lu]Lu-DOTA-TATE (hereafter 177Lu-DOTATATE) in adolescents with advanced, somatostatin receptor-positive, well-differentiated, Grade 1/2 gastroenteropancreatic neuroendocrine tumours (GEP-NET) or pheochromocytoma and paragangliomas (PPGL). Patients (12–17… read more here.
Keywords: dota tate; safety dosimetry; dosimetry; safety ... See more keywords